[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503981":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":17,"centralContacts":17,"locations":29,"responsibleParty":50,"collaborators":54,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":17,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":32,"whyStopped":17,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pharmaceutical intervention (OROS-MPH)","EXPERIMENTAL","Participants will receive OROS-MPH (Concerta® available in Switzerland as first-line treatment for ADHD). Dosages will be defined according to the Swiss Compendium. The psychiatrist (blinded during detention) will start with the smallest dosage (18 mg, Concerta®). The treatment will be monitored weekly the first month, and then monthly. The pharmacy of the Geneva University Hospitals will be in charge of over-encapsulating medications.",[13],"Drug: Concerta",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",null,[19],"Drug: Placebo",[21,26],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":17},"DRUG","Concerta","Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg\u002Fd).\n\nThe psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.\n\nThe treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release.",[9],{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":17},"The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).\n\nProcedure for adjustment of dosage will be the same as in the Concerta arm.",[15],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Geneva University Hospitals","RECRUITING","Geneva","Canton of Geneva","1211","Switzerland","CH",{"type":39,"coordinates":40},"Point",[41,42],6.14569,46.20222,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":17,"email":49},"Patrick Heller, MD","CONTACT","+41223055218","patrick.heller@hug.ch",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"SPONSOR_INVESTIGATOR","Stéphanie Baggio","Prof.",[55,57,59,62],{"name":56,"class":6},"University of Lausanne",{"name":58,"class":6},"University of Geneva, Switzerland",{"name":60,"class":61},"Netherlands Institute for the Study of Crime","UNKNOWN",{"name":63,"class":61},"School of Health Sciences Fribourg","100503981","phase-3-benefits-of-adhd-treatment-in-detained-people-100503981",false,"NCT05842330","Benefits of ADHD Treatment in Detained People","Benefits of In-prison OROS-methylphenidate vs. Placebo Treatment in Detained People With Attention-deficit\u002FHyperactivity Disorder: A Randomized Controlled Trial","BATIR","Inclusion Criteria:\n\n* age between 18 and 65\n* good command of French\n* stay in prison approx. 4 months at eligibility visit\n* endorsing clinical diagnostic criteria for DSM-5 ADHD\n* providing written informed consent\n\nExclusion Criteria:\n\n* presence of an acute uncontrolled comorbid psychiatric disorder\n* medical contraindication to stimulant prescription\n* potential adverse interaction with another medication\n* already receive ADHD treatment","ALL","18 Years","65 Years",{"count":76,"type":77},150,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3","Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.",[83],"ADHD",[85,86,87,88],"Prison","Health care","Adherence to treatment","Recidivism","2026-03-13",{"date":91,"type":92},"2026-03-17","ACTUAL",{"date":94,"type":92},"2024-01-01",{"date":96,"type":77},"2027-10-30",{"name":52,"class":6},1]